Moderators: i_like_bb_stock , Eagle1 , Threeflight , pepeoil , trader59 , Giffy
Search This Board: 
Created: 03/17/2009 02:37:40 PM - Followers: 313 - Board type: Free - Posts Today: 18
 
OTC: CUBT

http://CurativeBiotech.com

INVESTOR PRESENTATION

https://curativebiotech.com/news-and-media/presentations

Curative Biotechnology, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop an adjuvant for the COVID-19 vaccines which enhance antibody response.

Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com

Current Drug Pipeline  https://curativebiotech.com/pipeline

Treatments for six (6) Ocular conditions, one (1) Oncology, one (1) Infectious disease and one (1) vaccine adjunct candidate 

* Metformin eyedrops for treatment of Acute Macular Degeneration (AMD)
* Treatments for Stargardt's disease, Retinitis Pigementosa, Choroidereia, Diabetic Retinopathy and Late Onset Retinal Degeneration

* Treatment for Pediatric Brain Cancer(Gioblastoma)
*  Treatment for Symptomatic Rabies with potential for a Priority Review Voucher (PRV) with monteziation opportunity of over $100 Million
*  Development of a next generation COVID-19 vaccine for kidney failure patient population (immuno-compromised). Enhanced antibody titer levels rcorded when used as an adjunct with current vaccines
 


NATIONAL EYE INSITUTE STRATEGIC PLAN--Vision for the Future

https://www.nei.nih.gov/sites/default/files/2021-12/NEI-StrategicPlan-VisionForTheFuture_508_edit.pdf

Age-Related Macular Degeneration (AMD)

AMD is a visually threatening condition, most often found in patients over age 60. Early and Intermediate AMD are characterized by enlarged drusen behind the eye’s retina. Close to 10% of the world’s population is over 60, increasing the prevalence of age-related macular degeneration. Dry AMD accounts for 80-90% of AMD cases, while wet AMD is 10-20% of cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late stage dry AMD). Wet AMD is caused by blood vessels that leak in the retina. These abnormal blood vessels may leak fluids or blood into the back of the eye.

Curative Biotech will reformulate metformin to treat intermediate dry AMD and Geographic Atrophy for the first indications. Development to be led by the lead inventor on the NEI Patents, Dr. Kapil Bharti. Curative is in negotiations with NEI to conduct the first clinical trial. This product may be eligible for 505(b)(2) treatment as a reformulation of an already approved drug.

The global age-related macular degeneration (AMD) market is expected to attain a value of $8.9 billion by 2022

Stargardt Disease

Stargardt disease is a type of inherited age-related macular degeneration that causes vision loss in children or young adults.The retina contains light-sensing cells called photoreceptors, which include rods and cones. Rods are in the outer retina and help people when lighting is dim and dark. Cones are in the macula and help people see intricate visual detail and color. Both cones and rods negatively affected in Stargardt disease, cones are more strongly impacted in people who have Stargardt disease.

The Global Stargardt Disease Therapeutics Market is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7% during the forecast period (2023 - 2028).

Retinitis Pigmentosa

Retinitis pigmentosa (RP) is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. People with RP experience a gradual decline in their vision, because photoreceptors degenerate. Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells.  Retinitis Pigmentosa (RP), an acquired retinal condition that causes retinal depletion, is an uncommon illness. Its underlying manifestations are decreased night vision along with loss of fringe vision. It slowly causes visual impairment. There is no conclusive remedy for retinitis pigmentosa. Hence medical institutions and various research and development centers are researching to develop a full proof cure for this disease which is boosting the growth of global retinitis pigmentosa market.

 Various studies suggest that this disease affects about 1 in 4,000 individuals worldwide. Without treatment, patients permanently lose central vision by the age of 60.

Choroideremia

Choroideremia is a hereditary degeneration of the retina in males that causes a gradual loss of vision. It starts in early childhood with night-blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. The lack of a functional protein in the retina causes cell death that is followed by the gradual deterioration of the retinal pigment epithelium, photoreceptors, and the choroid. Choroideremia results in progressive loss of vision and is more prominent in males. The first symptom of choroideremia is usually night blindness that occurs at an early stage.
Vision loss occurs due to degeneration of light-sensitive tissue cell. Nearly every patient with choroideremia develops progressive reduction of vision at a later stage.

As per Center for Disease Control and Prevention (CDC), 1 in 50,000-100,000 among U. S. population is suffering from choroideremia disease. The Choroideremia disease is a genetic, rare and degenerative disorder with lack of specific treatment and currently there is unmet demand of novel treatments in the choroideremia treatment market.

Global Choroideremia Treatment market is expected to account for $4.3 Billion by 2028 

Late Onset Retinal Degeneration

Late-onset retinal degeneration occurs in adulthood and is an inherited retinal dystrophy. It leads to central vision loss.

https://www.sciencedaily.com/releases/2021/12/211209133927.htm

Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness in adults. It is a complication of diabetes that causes damage to the blood vessels of the retina. At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. and is expected to register a CAGR of 7.6% over the forecast period. Market growth can be primarily attributed to increased funding by regulatory bodies for researching ocular disorders.

The growing incidence of retinal disorders around the globe and the need for effective and affordable treatment options for the same has also driven the market. The National Eye Institute estimates that by 2030 and 2050, around 10 and 14 million people respectively will suffer from diabetic retinopathy in America.  The NCBI estimates that by 2040, individuals with early and late AMD will range between 14.9-21.5 million and 3.9-4.8 million respectively in Europe. The increasing geriatric population is also anticipated to be a major factor governing the overall market. According to data published in the World Population Prospects: 2019 Revision, around 1 in 11 and 1 in 4 people living in North America and Europe, respectively, will be aged 65 years and above by 2050.

REFERENCE LINK:  https://curativebiotech.com/pipeline

 

 
MANAGEMENT TEAM 
 
Paul M Michaels
Chairman and 
President
 
Barry A Ginsberg, O.D.
Chief Strategy Officer
 
I. Richard Garr, J.D.
CEO, General Counsel
 
Ronald W. Bordens, Ph.D.
EVP, Eng.& Ops.

SCIENTIFIC ADVISORY BOARD
 
Michael J. Grace, Ph.D
Chairman of Scientific Advisory Board
Has 30 years of executive and technical experience in both research and development of protein therapeutics and peptides within the biotechnology industry at Schering-Plough, Bristol Myers Squibb, NPS Pharma and Advaxis Inc. He has contributed to or personally led the development to commercial approval of 9 drugs by FDA and EMA including PEG-IntronTM, OrenciaTM, NulojixTM, YervoyTM, GattexTM and NatparaTM. His experience encompasses all aspects of drug development from discovery, process development, analytical development, quality control and regulatory affairs.
 
Kapil Bharti, Ph.D.
Advisor
From the National Eye Institute (NEI) at the National Institutes of Health (NIH) and is the lead inventor on the U.S. and Worldwide patent applications licensed exclusively to Curative Biotech to repurpose Metformin into an eye drop to treat degenerative eye diseases like macular degeneration, diabetic retinopathy, Stargardt’s disease, and others.
 
Dimiter S Dimitrov, Ph.D
Advisor

From 1990 to 2017, worked at National Cancer Insitute of the NIH. Since 2017 Director of  Center for Antibody Therapeutics at University of Pittsburgh. Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents. Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma.  

Nicholas Boullis, MD/Ph.D
Advisor
On the faculty of the Emory School of Medicine in Atlanta. Director of Emory University's Gene and Cell Therapy for Neurorestoration Laboratory. His research and clinical accomplishments include a path-breaking approach to spinal cord-delivered therapeutics and over 100 peer-reviewed publications in journals including Neurobiology Disease, Operative Neurosurgery, Clinical Neurology and Neurosurgery, Journal of Clinical Neuroscience, and Experimental Neurology, among others.

Catherine Sohn. Ph.D
Special Advisor to the Board of Director and CEO

Currently President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco. 

Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty (30) years of U.S. and global experience with expertise in the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.

Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc.

 
 Curative Biotech OTC Profile:
https://www.otcmarkets.com/stock/CUBT/overview
 

Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-gen COVID-19 Vaccine

License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies

Boca Raton, FL, October 7, 2021 (GLOBE NEWSWIRE) — Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) announced today that the Company has reached agreement with Mid-Atlantic BioTherapeutics (MABT) to broaden its previously announced license of IMT504, a novel patented immunotherapy and adjuvant, to include the development of a next generation COVID-19 vaccine. The Company will initially develop the vaccine to address the kidney failure patient population.  This new license, utilizing IMT504 as an adjuvant on top of a proprietary protein vaccine, adds a second infectious disease program to the Curative Biotech product development portfolio which also includes a reformulation of Metformin licensed from the National Eye Institute at National Institutes of Health (NIH) to treat degenerative eye diseases; and a novel monoclonal antibody/drug combination to treat brain cancer licensed from the National Cancer Institute at NIH.

“It is becoming increasingly clear that the initial COVID-19 vaccines developed are not working for everyone.  There are highly vulnerable people, such as those patients with kidney failure who require kidney transplantation or dialysis, who are being left behind.  We need targeted vaccines for this immunocompromised patient group,” said Curative Biotech Chairman & President Paul Michaels.

Curative Biotech and Mid-Atlantic BioTherapeutics have agreed to develop a next generation COVID-19 vaccine targeted to meet the needs of this vulnerable population.  A consequence of kidney failure in general is the loss of a robust immunologic response to infections, including COVID-19.  This means that kidney failure patients may get a more severe version of COVID-19 that could lead to a greater chance of hospitalization or even death.

Dr. David Horn, CEO of Mid-Atlantic BioTherapeutics, added: “It is well known that kidney transplant recipients have impaired responses to mRNA COVID-19 vaccines.  Recent data from France reveals that, even after 4 vaccine shots, many kidney transplant recipients have poor responses. In addition, kidney failure patients on dialysis do not initially respond as well to current vaccines and rapidly lose measurable antibodies when compared to the general population.”

As previously announced, Curative Biotech has acquired the worldwide rights for the development of IMT504 to treat symptomatic rabies.   Curative Biotech and MABT are already working together to develop IMT504 to treat patients whose disease has advanced to a stage where the virus has migrated to the brain, causing lethal rabies encephalitis. There are currently no treatment options for these patients. IMT504 has already been granted orphan drug designation in the US for the treatment of rabies, which may provide significant benefits including tax credits, market exclusivity and the waiver of certain FDA fees. Rabies is one of only a limited number of diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria. Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance, and it can be sold to another party.

Chairman Michaels concluded, “We are excited to begin work on this additional program and expect to announce additional important management resources at Curative Biotech to supplement the clinical development team.”

Future Curative Biotechnology Press Releases and Industry Updates

Interested investors and shareholders will receive press releases and industry updates by sending an e-mail to ir@curativebiotech.com.

About Mid-Atlantic BioTherapeutics, Inc. https://mabt.us/

Mid-Atlantic BioTherapeutics was founded in 2011 with the mission of eradicating infectious diseases. MABT is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of novel anti-infective approaches, such as the patented IMT504 immunotherapy platform, that harnesses the body’s own immune response to fight off infections. The company is actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for bacterial and viral diseases, emerging infectious diseases, and biodefense.

About Curative Biotechnology, Inc. http://curativebiotech.com

Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare or currently unmet medical needs. Curative Biotech is focused on therapies with potentially accelerated development paths resulting from either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a therapeutic option.

Contact:

Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com

LINK  https://www.biospace.com/article/releases/curative-biotechnology-announces-imt504-license-for-development-of-proprietary-next-gen-covid-19-vaccine/

Connectyx (now Curative Botechnology) Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).

The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide.

The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.

Research has shown that Metformin, an FDA-approved drug that has been widely used for the treatment of diabetes in the United States since 1995, can activate AMP-activated protein kinase, can reduce vascular endothelial growth factor (VEGF) secretion, and can correct baseline calcium levels in patient RPE cells. The new treatment indications will require reformulating the drug into an eye drop, injectable or other topical delivery method to be able to deliver sufficient drug to the RPE layer to have a therapeutic effect. This reformulated drug should be eligible for a 505(b)(2) accelerated development path. While the field of use covers treating any degenerative eye disease, the Company is targeting Stargardt, a currently untreatable orphan disease that causes vision loss in children, as the first indication for this therapeutic product.

Paul Michaels, Chairman and President of Connectyx, said, “We are pleased to expand our product portfolio with the addition of reformulated and repurposed Metformin, which is the fifth most prescribed drug in the United States. This very promising product adds a second in licensed product from the NIH to our development portfolio. As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss. We are focused on developing disease modifying therapeutics to meet the unmet needs of patients. The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.”

About Age-Related Macular Degeneration, Stargardt Disease, Retinitis Pigmentosa and Choroideremia

AMD is the leading cause of vision loss in people ages 60+. It destroys a patient’s sharp, central vision. Stargardt disease is a type of AMD that causes vision loss in children or young adults. Retinitis pigmentosa is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. Choroideremia is a hereditary retinal degeneration that causes a gradual loss of vision. It starts in early childhood with night blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. Diabetic retinopathy is the leading cause of blindness in adults. Diabetes harms blood vessels inside the eye by weakening them so they leak fluid into the retina, which can damage areas of the retina, causing blurry, distorted vision.

About Mid-Atlantic BioTherapeutics

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity.  

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#37692
It is a toxic note with $142K taken trader59 03/10/2022 05:42:55 PM
#30408
CTYX DD Packet with hyper links! http://tinyurl.com/curativebiodd Connectyx ( Eagle1 02/06/2021 10:30:12 PM
#29144
This turd does not have the right to pepeoil 12/07/2020 12:45:36 PM
#28773
DD on why this is not a game: https://investorshub.advfn.com/boards/read_ RiseandShine 11/01/2020 01:31:59 AM
#38756
The timing and the reverse ratio are still unknown. Student of the Game 06/30/2022 11:14:49 AM
#38755
What’s the timing of the proposed RS and govprs 06/30/2022 11:05:33 AM
#38754
What I’m saying is Khapil Bharti is the iRobot 06/30/2022 10:45:52 AM
#38753
Well I’m curious about that because in this iRobot 06/30/2022 10:37:15 AM
#38751
Well there must be a few people that iRobot 06/30/2022 10:33:16 AM
#38750
Not a chance. If the drug were trader59 06/30/2022 10:32:45 AM
#38749
A warrant is essentially an option to buy trader59 06/30/2022 10:31:08 AM
#38748
Their drug is worth 3 to 6 billion. baberuth1974 06/30/2022 10:27:44 AM
#38747
Tell me how it’s all good are you iRobot 06/30/2022 10:26:41 AM
#38746
Its all good people. $ on baberuth1974 06/30/2022 10:19:41 AM
#38745
Forgive my ignorance, but what is a warrent,? newmanhead 06/30/2022 07:44:21 AM
#38744
No, it didn’t. It was pumped to trader59 06/30/2022 06:57:48 AM
#38743
It's time to understand the business model. Student of the Game 06/30/2022 06:52:09 AM
#38742
Uplisting but no office. Bwahaaaaaa pepeoil 06/30/2022 05:39:03 AM
#38741
Cubt needs another bod. It pepeoil 06/30/2022 05:38:16 AM
#38740
Man, V*rb went to $45 , so your pacman181 06/30/2022 03:53:28 AM
#38739
What if they do not have the capital conix 06/30/2022 12:28:47 AM
#38738
At this point I can say that it's Vanasn 06/29/2022 11:27:33 PM
#38737
Do you understand the only reason they would iRobot 06/29/2022 10:42:18 PM
#38735
Great idea--"all they have to do is drop conix 06/29/2022 09:45:12 PM
#38734
Well, it looks like we will be seeing conix 06/29/2022 09:41:09 PM
#38733
I mean if they really already already applied iRobot 06/29/2022 09:15:00 PM
#38732
So you don’t think that if they come iRobot 06/29/2022 09:01:16 PM
#38731
All of those had presumably viable products described trader59 06/29/2022 08:55:03 PM
#38730
Not saying that you’re wrong but I am iRobot 06/29/2022 08:39:20 PM
#38729
We need to get the price of the iRobot 06/29/2022 08:35:23 PM
#38728
The 6 uplists with RS I've observed have trader59 06/29/2022 08:13:34 PM
#38727
I am delighted to see that there is Student of the Game 06/29/2022 07:54:28 PM
#38726
And this isn’t true you can clearly look iRobot 06/29/2022 06:53:14 PM
#38725
Know what I care about is this company iRobot 06/29/2022 06:52:17 PM
#38724
And if this was true it wouldn’t be iRobot 06/29/2022 06:51:25 PM
#38722
In the S one it clearly says since iRobot 06/29/2022 06:48:58 PM
#38716
So they want to get on the New iRobot 06/29/2022 06:08:45 PM
#38715
What I don’t like is it seems that iRobot 06/29/2022 06:03:43 PM
#38714
They won't know how many warrants or the trader59 06/29/2022 05:38:00 PM
#38713
Updated S/1 just dropped on otcmarkets.com. Looks tdgnts 06/29/2022 05:07:58 PM
#38712
What was the news that they released? iRobot 06/28/2022 02:51:28 PM
#38711
What is going on with this stock did iRobot 06/28/2022 02:46:16 PM
#38710
This stock is doing the same shit it iRobot 06/28/2022 01:51:37 PM
#38709
Answer the question man you said 30 more iRobot 06/28/2022 01:56:02 AM
#38708
Someone wanted in today. Nice chart ! Eagle1 06/27/2022 09:57:04 PM
#38707
I’m curious how do you know this? As iRobot 06/27/2022 09:30:24 PM
#38706
About 30 more days of rabbit trials. newmanhead 06/27/2022 08:40:16 PM
#38705
Waiting on solid results on what? the animal trials? iRobot 06/27/2022 08:34:18 PM
#38704
Waiting on solid results, until then ZZZZZZ 1King313 06/27/2022 07:39:46 PM
#38703
Man this boards dead I think a lot iRobot 06/27/2022 03:52:34 PM
#38702
Why are you responding to a post from iRobot 06/22/2022 10:58:18 PM
#38701
All depends on your agenda.... bigrun 06/22/2022 09:06:38 PM
#38699
Yep, that brings the total to 937 board pepeoil 06/21/2022 05:00:09 AM
#38698
Wow ! More share gifting. lizardlover 06/21/2022 03:00:02 AM
Post Subject